Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-label, Efficacy and Safety Study of AR882 and XOI Co-administration in Participants With Uncontrolled Gout Who Have Previously Failed Uricase Treatment

NCT07116746 is registered in ClinicalTrials.gov with Arthrosi Therapeutics as lead sponsor.

NCT NCT07116746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07116746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-label, Efficacy and Safety Study of AR882 and XOI Co-administration in Participants With Uncontrolled Gout Who Have Previously Failed Uricase Treatment
Lead sponsor
Arthrosi Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 3, 2025
Completion date
February 28, 2027
Enrollment
15 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

gout, gout chronic, gouty arthritis, hyperuricemia, refractory gout, tophaceous gout, uncontrolled gout